The study of human breast cancer cells has revealed that some breast cancer medicines may create ‘sleeper cells’ – allowing them to potentially come back to life years after the initial treatment.
The team from Imperial College London studied a group of breast cancer drugs called hormone treatments. The new research will help to find ways of keeping the cancer cells dormant for longer, or even potentially finding a way of awakening the cells so they can then be killed by the treatment.
Dr Luca Magnani, lead author of the study from Imperial’s Department of Surgery and Cancer said: “For a long time scientists have debated whether hormone therapies – which are a very effective treatment and save millions of lives – work by killing breast cancer cells or whether the drugs flip them into a dormant ‘sleeper’ state.
“This is an important question as hormone treatments are used on the majority of breast cancers. Our findings suggest the drugs may actually kill some cells and switch others into this sleeper state. If we can unlock the secrets of these dormant cells, we may be able to find a way of preventing cancer coming back, either by holding the cells in permanent sleep mode, or be waking them up and killing them.”
Sleeper cells may become resistant to treatment
Around 50,000 human breast cancer single cells were studied in the lab, and found that treating them with hormones exposed a small proportion of them as being in a dormant state.
‘Sleeper cells’ may also provide clues as to why some breast cancer cells become resistant to treatment – causing a patient’s drugs to stop working, and their cancer to return.
Hormone therapies are used to treat a type of breast cancer called oestrogen-receptor positive which make up over 70% of all breast cancers. These are fuelled by the hormone oestrogen and are usually treated with surgery to remove the tumour, followed by a course of targeted hormone therapy. This is usually either aromatase inhibitors or tamoxifen, which target oestrogen receptors.
However, around 30% of breast cancer patients taking hormone therapies see their cancer eventually return – sometimes as long as 20 years after treatment. This returning cancer is usually metastatic, meaning it has spread around the body, and the tumours are often now resistant to medication.
Cells might make their own fuel
Previous work by the same team has suggested that cells can make their own ‘fuel’, allowing them to avoid being ‘starved’ by cancer treatment.
This new research provides another piece in the puzzle, explained Dr Iros Barozzi, co-author of the study, also from the Department of Surgery and Cancer: “These sleeper cells seem to be an intermediate stage to the cells becoming resistant to the cancer drugs. The findings also suggest the drugs actually trigger the cancer cells to enter this sleeper state.”
Cells that lie in this dormant sleeper state were more likely to spread around the body, explained Dr Sung Pil Hong, study co-author from Imperial: “Our experiments suggest these sleeper cells are more likely to travel around the body. They could then ‘awaken’ once in other organs of the body and cause secondary cancers. However, we still don’t know how these cells switch themselves into sleep mode and what would cause them to wake up. These are questions that need to be addressed with further research.”
According to the researchers, hormone therapies remain one of the most effective treatments against breast cancer.
Further patient research will explore whether taking hormone therapies for longer after initial cancer treatment could prevent cancer cells from waking from their sleeping state.
Dr Rachel Shaw, Cancer Research UK, said: “Although treatments for breast cancer are usually successful, cancer returns for some women, often bringing with it a poorer prognosis. Figuring out why breast cancer sometimes comes back is essential to help us develop better treatments and prevent this from happening.
“This study highlights a key route researchers can now explore to tackle ‘sleeping’ cancer cells that can wake up years after treatment, which could potentially save the lives of many more women with the disease.”
The study was published in the journal Nature Communications and funded by Cancer Research UK and the NIHR Imperial Biomedical Research Centre